Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 29 | 2025 | 280 | 8.840 |
Why?
|
| Antipsychotic Agents | 11 | 2025 | 307 | 3.140 |
Why?
|
| Mental Disorders | 7 | 2023 | 824 | 2.730 |
Why?
|
| Psychodrama | 2 | 2022 | 2 | 1.420 |
Why?
|
| Substance-Related Disorders | 3 | 2025 | 749 | 1.340 |
Why?
|
| Quinolones | 2 | 2025 | 30 | 1.290 |
Why?
|
| Metabolic Syndrome | 3 | 2021 | 147 | 1.230 |
Why?
|
| Graphite | 4 | 2024 | 15 | 1.170 |
Why?
|
| Nitric Oxide | 2 | 2020 | 181 | 1.100 |
Why?
|
| Clozapine | 2 | 2019 | 32 | 0.960 |
Why?
|
| Thiophenes | 1 | 2025 | 31 | 0.920 |
Why?
|
| Metabolic Diseases | 2 | 2016 | 59 | 0.820 |
Why?
|
| Help-Seeking Behavior | 1 | 2023 | 10 | 0.790 |
Why?
|
| Neurotransmitter Agents | 2 | 2019 | 43 | 0.750 |
Why?
|
| Mental Health Recovery | 1 | 2022 | 5 | 0.740 |
Why?
|
| Drama | 1 | 2022 | 5 | 0.740 |
Why?
|
| Connectome | 2 | 2019 | 36 | 0.740 |
Why?
|
| Methamphetamine | 2 | 2019 | 25 | 0.720 |
Why?
|
| Insulin | 3 | 2019 | 694 | 0.700 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 224 | 0.660 |
Why?
|
| Psychotic Disorders | 3 | 2021 | 164 | 0.620 |
Why?
|
| Mindfulness | 1 | 2021 | 70 | 0.620 |
Why?
|
| Humans | 38 | 2025 | 65554 | 0.620 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2019 | 5 | 0.620 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 24 | 0.600 |
Why?
|
| Renin-Angiotensin System | 1 | 2019 | 23 | 0.600 |
Why?
|
| Gyrus Cinguli | 1 | 2019 | 59 | 0.600 |
Why?
|
| Art Therapy | 1 | 2019 | 6 | 0.600 |
Why?
|
| Infection Control | 1 | 2020 | 105 | 0.600 |
Why?
|
| Community Health Services | 1 | 2020 | 127 | 0.590 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 28 | 0.580 |
Why?
|
| Nerve Net | 1 | 2019 | 101 | 0.570 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 47 | 0.570 |
Why?
|
| Hospitals, General | 1 | 2018 | 17 | 0.560 |
Why?
|
| Adult | 21 | 2025 | 17417 | 0.550 |
Why?
|
| Minocycline | 1 | 2018 | 28 | 0.550 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2014 | 35 | 0.540 |
Why?
|
| Double-Blind Method | 6 | 2022 | 749 | 0.540 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 208 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 222 | 0.510 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 249 | 0.500 |
Why?
|
| Health Status Disparities | 1 | 2018 | 146 | 0.490 |
Why?
|
| Inpatients | 1 | 2019 | 311 | 0.480 |
Why?
|
| Young Adult | 14 | 2019 | 4831 | 0.470 |
Why?
|
| Uric Acid | 1 | 2016 | 48 | 0.470 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 42 | 0.460 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 175 | 0.460 |
Why?
|
| Health Behavior | 1 | 2019 | 482 | 0.450 |
Why?
|
| Pandemics | 1 | 2020 | 676 | 0.450 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 483 | 0.450 |
Why?
|
| Antioxidants | 1 | 2017 | 266 | 0.450 |
Why?
|
| Telemedicine | 1 | 2020 | 361 | 0.440 |
Why?
|
| Dietary Supplements | 1 | 2017 | 239 | 0.440 |
Why?
|
| Male | 21 | 2025 | 31083 | 0.420 |
Why?
|
| Registries | 1 | 2018 | 904 | 0.410 |
Why?
|
| Mental Health Services | 1 | 2018 | 308 | 0.410 |
Why?
|
| Female | 21 | 2025 | 34131 | 0.400 |
Why?
|
| Schizophrenic Psychology | 4 | 2018 | 75 | 0.400 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2025 | 89 | 0.390 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2022 | 393 | 0.390 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 271 | 0.380 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 866 | 0.370 |
Why?
|
| Piperazines | 1 | 2012 | 87 | 0.360 |
Why?
|
| Lipid Metabolism | 2 | 2014 | 228 | 0.360 |
Why?
|
| Microelectrodes | 2 | 2022 | 14 | 0.360 |
Why?
|
| Body Weight | 4 | 2019 | 381 | 0.340 |
Why?
|
| Treatment Outcome | 7 | 2025 | 5822 | 0.330 |
Why?
|
| Cognition | 2 | 2022 | 502 | 0.330 |
Why?
|
| Comorbidity | 3 | 2019 | 1126 | 0.310 |
Why?
|
| Middle Aged | 11 | 2025 | 18277 | 0.310 |
Why?
|
| Adolescent | 10 | 2019 | 6377 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2510 | 0.300 |
Why?
|
| Biomarkers | 5 | 2018 | 1473 | 0.280 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 473 | 0.260 |
Why?
|
| Risperidone | 2 | 2018 | 25 | 0.250 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 260 | 0.240 |
Why?
|
| Obesity | 1 | 2014 | 1269 | 0.240 |
Why?
|
| Body Composition | 2 | 2019 | 154 | 0.230 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2022 | 25 | 0.230 |
Why?
|
| Lipoproteins, LDL | 2 | 2016 | 49 | 0.210 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 122 | 0.210 |
Why?
|
| Cytokines | 3 | 2019 | 956 | 0.210 |
Why?
|
| Body Mass Index | 3 | 2019 | 888 | 0.200 |
Why?
|
| Administration, Intranasal | 2 | 2013 | 27 | 0.200 |
Why?
|
| Acculturation | 1 | 2023 | 38 | 0.190 |
Why?
|
| Glucose | 2 | 2019 | 478 | 0.190 |
Why?
|
| Hippocampus | 2 | 2015 | 280 | 0.190 |
Why?
|
| Independent Living | 1 | 2023 | 55 | 0.190 |
Why?
|
| Absorptiometry, Photon | 2 | 2013 | 77 | 0.190 |
Why?
|
| Isoelectric Focusing | 1 | 2022 | 13 | 0.190 |
Why?
|
| Social Stigma | 1 | 2023 | 75 | 0.190 |
Why?
|
| Patient Care | 1 | 2022 | 79 | 0.180 |
Why?
|
| Berberine | 1 | 2022 | 4 | 0.180 |
Why?
|
| Biosensing Techniques | 1 | 2023 | 124 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 2248 | 0.180 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2021 | 28 | 0.170 |
Why?
|
| Craving | 1 | 2021 | 38 | 0.160 |
Why?
|
| Focus Groups | 1 | 2022 | 322 | 0.160 |
Why?
|
| Multimorbidity | 1 | 2021 | 50 | 0.160 |
Why?
|
| Social Isolation | 1 | 2020 | 38 | 0.160 |
Why?
|
| Mental Health | 1 | 2023 | 379 | 0.160 |
Why?
|
| Electroacupuncture | 1 | 2019 | 3 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2700 | 0.150 |
Why?
|
| Putamen | 1 | 2019 | 21 | 0.150 |
Why?
|
| Attention | 1 | 2021 | 150 | 0.150 |
Why?
|
| Arginine | 1 | 2020 | 134 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 460 | 0.150 |
Why?
|
| Aged | 4 | 2018 | 14958 | 0.150 |
Why?
|
| Exercise Therapy | 1 | 2019 | 104 | 0.140 |
Why?
|
| Siblings | 1 | 2018 | 43 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 126 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 495 | 0.140 |
Why?
|
| Quality of Life | 1 | 2025 | 1270 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2019 | 1018 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 351 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2019 | 323 | 0.130 |
Why?
|
| Triglycerides | 1 | 2019 | 250 | 0.130 |
Why?
|
| Proteins | 1 | 2022 | 764 | 0.120 |
Why?
|
| Time Factors | 2 | 2013 | 3788 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2013 | 612 | 0.110 |
Why?
|
| Inflammation | 2 | 2019 | 1186 | 0.110 |
Why?
|
| Pravastatin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Anticholesteremic Agents | 1 | 2014 | 35 | 0.110 |
Why?
|
| Homocysteine | 1 | 2014 | 33 | 0.110 |
Why?
|
| Folic Acid | 1 | 2014 | 43 | 0.110 |
Why?
|
| Apolipoprotein A-I | 1 | 2014 | 23 | 0.110 |
Why?
|
| Th17 Cells | 1 | 2014 | 62 | 0.100 |
Why?
|
| Sex Factors | 2 | 2015 | 997 | 0.100 |
Why?
|
| Adiponectin | 1 | 2013 | 38 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 403 | 0.100 |
Why?
|
| Homeostasis | 1 | 2016 | 376 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2013 | 47 | 0.100 |
Why?
|
| Aripiprazole | 1 | 2012 | 5 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1114 | 0.100 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 116 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2016 | 413 | 0.090 |
Why?
|
| Benzodiazepines | 1 | 2013 | 106 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 98 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 296 | 0.090 |
Why?
|
| Phenotype | 1 | 2014 | 1241 | 0.080 |
Why?
|
| Feces | 2 | 2022 | 117 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1606 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 694 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1156 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 5620 | 0.060 |
Why?
|
| Risk Factors | 1 | 2016 | 5441 | 0.060 |
Why?
|
| Cellular Microenvironment | 1 | 2024 | 23 | 0.060 |
Why?
|
| United States | 1 | 2018 | 8131 | 0.050 |
Why?
|
| DNA Probes | 1 | 2023 | 35 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2023 | 100 | 0.050 |
Why?
|
| Hybridization, Genetic | 1 | 2023 | 34 | 0.050 |
Why?
|
| Calcium Signaling | 1 | 2024 | 165 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2024 | 468 | 0.050 |
Why?
|
| Fungi | 1 | 2022 | 62 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 24 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2022 | 21 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2022 | 74 | 0.040 |
Why?
|
| Physical Phenomena | 1 | 2021 | 9 | 0.040 |
Why?
|
| Polymethyl Methacrylate | 1 | 2021 | 15 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2021 | 73 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 167 | 0.040 |
Why?
|
| Copper | 1 | 2021 | 56 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 321 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2024 | 728 | 0.040 |
Why?
|
| Bacteria | 1 | 2022 | 338 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2019 | 121 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2018 | 25 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 855 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 22 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 1793 | 0.030 |
Why?
|
| Animals | 2 | 2024 | 21533 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 146 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2014 | 12 | 0.030 |
Why?
|
| Chromogranins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Immunoassay | 1 | 2014 | 71 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 173 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2014 | 223 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 674 | 0.020 |
Why?
|
| Proteomics | 1 | 2014 | 306 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 492 | 0.020 |
Why?
|